

SEQ ID NO: 1 or an analyte thereof related to said disease state; and means for determining binding between said biochemical material and said biomolecule; whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

(*A P C A D C I*)

25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal antibody specific therefore.

(*A P C A D C I*)

29. Polyclonal antibodies produced against the marker having a sequence identified as SEQ ID NO: 1 in at least one animal host.

(*A P C A D C I*)

30. An antibody that specifically binds a biopolymer including the marker having a sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

(*A P C A D C I*)

33. A process for identifying therapeutic avenues related to a disease state comprising: conducting an analysis as provided by the kit of claim 18; and interacting with a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof;

whereby therapeutic avenues are developed.

(*A P C A D C I*)

34. The process for identifying therapeutic avenues related to a disease state in